Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02351180 |
Other study ID # |
WUIBCARV1-201404080 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 1/Phase 2
|
First received |
|
Last updated |
|
Start date |
February 1, 2017 |
Est. completion date |
January 31, 2021 |
Study information
Verified date |
January 2022 |
Source |
Washington University School of Medicine |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to determine if the use of inhaled beclomethasone after a
community-acquired respiratory viral infection in a lung transplant recipient decreases the
risk of the subsequent development of chronic lung allograft dysfunction.
Description:
Community-acquired respiratory viral (CARV) infections after lung transplantation are
associated with an increased risk for the development of chronic lung allograft dysfunction
(CLAD) after lung transplantation. The exact mechanisms whereby CARV infections increase this
risk are unknown. We propose that viral infection results in airway epithelial cell injury
and the expression of injury-response genes that provide signals that initiate immunologic
and non-immunologic pathways that result in the airway remodeling characteristic of
obliterative bronchiolitis, the predominant pathology of CLAD. Systemic and inhaled
corticosteroids are frequently used as anti-inflammatory agents to treat the peribronchiolar
inflammation seen in viral bronchiolitis. Beneficial effects from corticosteroids have been
reported, but this has not been demonstrated in lung transplant recipients. The aim of this
single center, randomized, double blind, placebo controlled study is to evaluate the short
and long term effects of a 6 month course of inhaled beclomethasone on adult lung transplant
recipients with CARV infection.